Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Fremanezumab for Migraine
Recruiting2 awardsPhase 4
Portland, Oregon
This trial is evaluating the efficacy of fremanezumab in adult patients with migraine and major depressive disorder. The objectives are to assess the reduction of MDD symptoms, responder rates in monthly migraine days, improving quality of life, improving disability, and the safety and tolerability of monthly 225 mg sc and quarterly 675 mg sc fremanezumab.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.